News EirGenix Inc.

Equities

6589

TW0006589005

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
83.1 ^TWD	+2.34%		+4.01%	-17.31%

Mar. 22	EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Mar. 08	EirGenix, Inc. Resolves to Sign the Contract with Clinical CRO and the Relevant Companies for Phase III Clinical Trail of the EG1206A	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 22	CI
EirGenix, Inc. Resolves to Sign the Contract with Clinical CRO and the Relevant Companies for Phase III Clinical Trail of the EG1206A	Mar. 08	CI
EirGenix Inc.'s Breast Cancer Biosimilar Receives Marketing Authorization by EC	Nov. 22	CI
EirGenix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13	CI
EirGenix Inc. Announces the Establishment of Phase II Facility and Production Equipment in Zhubei	Nov. 09	CI
Novartis' Sandoz Unit Says European Medicines Agency Panel Supports Approval of Trastuzumab Biosimilar	23-09-18	MT
Novartis Cancer Drug Gets Marketing Recommendation from European Medicines Agency	23-09-18	DJ
Novartis Unit Wins European Medicines Agency's Positive Opinion for Breast Cancer Biosimilar	23-09-18	MT
National Health Insurance Administration Approves EirGenix Inc.'S Biosimilar, Eirgasun Vial 150 Mg to Be Enrolled in the Reimbursement System	23-09-18	CI
EirGenix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
EirGenix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
EirGenix Inc. Completes the Phase 1 Clinical Trial of Its Second Breast Cancer Biosimilar EG1206A in Europe	23-05-02	CI
EirGenix Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-20	CI
EirGenix Inc. announced a financing transaction	23-03-09	CI
EirGenix Inc. Announces Executive Changes	23-01-10	CI
Eirgenix Inc. Announces Establishment of Corporate Governance Committee	22-12-28	CI
EirGenix Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
Eirgenix, Inc., Submits the Biosimilar Drug Eirgasum of 150 Mg Powder for Concentratefor Solution for Infusion Presentation New Drug Application to the Taiwan Food and Drug Administration	22-09-30	CI
EirGenix Inc. Appoints Po-Chih Chen as Remuneration Committee	22-09-08	CI
EirGenix Inc. Announces Board Changes	22-09-07	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News EirGenix Inc.

Equities

6589

TW0006589005

Summary

Filters